Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTI Seeks ASP Payment For Zevalin; Medicare Cap Temporarily Lifted

Executive Summary

After winning a short-term reprieve from Medicare's payment cap on radioimmunotherapies, Cell Therapeutics will focus on convincing CMS to pay for those drugs under Part B's average sales price formula

You may also be interested in...



Comparative Effectiveness Bill Calls For Private Group To Plan Research

While getting little exposure in the new Medicare law, comparative effectiveness research is getting full attention in a bill introduced by Sen. Max Baucus, D-Mont., that offers a comprehensive roadmap toward conducting the research and disseminating findings

Comparative Effectiveness Bill Calls For Private Group To Plan Research

While getting little exposure in the new Medicare law, comparative effectiveness research is getting full attention in a bill introduced by Sen. Max Baucus, D-Mont., that offers a comprehensive roadmap toward conducting the research and disseminating findings

CMS Open To ASPs For Radiopharmaceuticals; Congress Blocks Rate Cap

CMS is willing to consider switching Medicare Part B payment for radiopharmaceuticals to the average sales price formula, the agency says in proposed rules to update Medicare's hospital outpatient prospective payment system for 2009

Related Content

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel